Amgen Seeks FDA OK for Monthly Single Shot Repatha
This article was originally published in Scrip
Executive Summary
Amgen is seeking the FDA's blessing to market a single-dose subcutaneous shot of its newly approved cholesterol-lowering drug Repatha (evolocumab) for patients who need the monthly dosage.